Dry eye diseases continue to remain a major health problem for millions of patients worldwide. As per the report published by the International Dry Eye Workshop II (DEWS II), dry eye is a multifactorial disease that is caused by the homeostasis loss of the tear film and other ocular symptoms. There are two major types of dry eye diseases as per the pathophysiological classification– aqueous deficient dry eye (ADDE) and evaporative dry eye (EDE). At present, considerable research and development activities are being focused on improving management and treatment of dry eyes by taking into account etiological distinctions.
Research and development activities are also expected to play an imperative role in new treatment strategies that are in sync with dry eye identification and diagnosis criteria. In recent years, tear film-oriented therapy has gained considerable traction worldwide due to which, the global dry eye disease diagnostics & treatment market is likely to witness a considerable boost during the forecast period. In addition, recent advancements in the medical technology and a growing understanding of pathophysiology, along with risk factors and etiology of dry eye disease, have led to the progress of new therapies.
At the back of these factors, along with the growing emphasis on research and development activities, the global dry eye disease diagnostics & treatment market is on the course to reach US$ 9.8 Bn by the end of 2030.
Despite considerable progress and advancements made in dry eye disease diagnostic and treatment, there continues to remain a considerable unmet medical requirement for efficient and highly effective dry eye treatments due to which, research and development activities have gained considerable momentum over the past decade. Due to surplus in the number of research activities, promising treatment and innovative products are currently in the pipeline awaiting approval from the FDA. Due to limited efficacy of current dry eye treatment and diagnostic alternatives, a range of companies in the dry eye disease diagnostics & treatment market has joined the race toward discovering an effective and treatment for dry eye diseases.
One of the most common dry eye diseases is the chronic inflammatory disease, which continues to affect the quality of life of millions of people worldwide. Due to major shortcomings of existing treatments for dry eye diseases, the focus in the dry eye disease diagnostics & treatment market primarily shifted toward drug development and new treatments. Several companies are currently in the process of developing new drugs or waiting for the approval of the FDA for their newly developed alternatives. For instance, Kala Pharmaceuticals recently submitted a drug application to the FDA for a new drug– KPI-121 for dry eye treatment due to considerable encouragement received in phase one and phase two trials. Similarly, Aldeyra Therapeutics is currently enrolling patients for phase three clinical trials in which, the efficacy of the newly developed reproxalap ophthalmic solution is likely to be evaluated. Research and development activities coupled with a flurry of promising products in the pipeline are set to open up new avenues for players operating in the current dry eye disease diagnostics & treatment market.
The ongoing COVID-19 pandemic is expected to have a short-term impact on the overall growth of the global dry eye disease diagnostics & treatment market. In terms of clinical trials and research, activities are likely to remain unaffected due to the exemption provided by governments. In addition, as scientists and researchers continue to explore the link between the novel coronavirus and its effect on patients suffering from dry eye diseases, research activities are projected to remain seamless. In terms of in-person appointments with patients, numbers are likely to witness a considerable drop, as several eye care professionals are increasingly turning toward telemedicine services for routine checkups. The demand for dry eye disease diagnostic and treatment, particularly in the first two quarters of 2020, is expected to remain sluggish. However, the dry eye disease diagnostics & treatment market is projected to show signs of recovery in the latter half of 2020 and continue to grow at a faster rate in 2021.
Analysts’ Viewpoint
The global dry eye disease diagnostics & treatment market is anticipated to grow at a moderate CAGR of ~4% during the forecast period. The market growth can be primarily attributed to factors such as growing prevalence of dry eye diseases worldwide, advancements in medical technology, focus on research and development activities, and promising pipeline products and therapies. Market players should focus on research activities to discover cost-efficient and highly effective treatment and drugs for dry eye disease treatment. Moreover, market players should focus on product diversification mainly during the pandemic, and offer products that are in demand during the COVID-19 crisis.
Dry eye disease diagnostics & treatment market to reach valuation of US$ 9.8 Bn by 2030.
Dry eye disease diagnostics & treatment market to expand at a CAGR of ~4% from 2020 to 2030.
Rise in prevalence & incidence rates of dry eye disease and increase in geriatric population are the Key factors boosting the dry eye disease diagnostics & treatment market.
North America is more attractive for vendors in the dry eye disease diagnostics & treatment market.
Key players in the global dry eye disease diagnostics & treatment market include Novartis AG, Allergan plc, OASIS Medical, Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Dry Eye Disease Diagnostics & Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Key Mergers & Acquisitions
5.5. COVID-19 Pandemics Impact on Industry (short / mid / long term impact)
6. Global Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2018–2030
6.3.1. Diagnostic Test
6.3.1.1. Schirmer’s Test
6.3.1.2. Corneal Staining
6.3.1.3. Tear Break-up Time (TBUT)
6.3.1.4. Optical Coherence Tomography (OCT)
6.3.1.5. Tear Film Stability Analysis
6.3.1.6. Tear Osmolarity
6.3.1.7. Others
6.3.2. Treatment
6.3.2.1. Artificial Tears
6.3.2.2. Anti-inflammatory
6.3.2.2.1. Cyclosporine
6.3.2.2.2. Corticosteroid
6.3.2.2.3. Others
6.3.2.3. Punctal Plugs
6.3.2.4. Secretagogue
6.3.2.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast, by Disease
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease, 2018–2030
7.3.1. Evaporative Dry Eye Syndrome
7.3.2. Aqueous Dry Eye Syndrome
7.4. Market Attractiveness Analysis, by Disease
8. Global Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2018–2030
9.2.1. Diagnostic Test
9.2.1.1. Schirmer’s Test
9.2.1.2. Corneal Staining
9.2.1.3. Tear Break-up Time (TBUT)
9.2.1.4. Optical Coherence Tomography (OCT)
9.2.1.5. Tear Film Stability Analysis
9.2.1.6. Tear Osmolarity
9.2.1.7. Others
9.2.2. Treatment
9.2.2.1. Artificial Tears
9.2.2.2. Anti-inflammatory
9.2.2.2.1. Cyclosporine
9.2.2.2.2. Corticosteroid
9.2.2.2.3. Others
9.2.2.3. Punctal Plugs
9.2.2.4. Secretagogue
9.2.2.5. Others
9.3. Market Value Forecast, by Disease, 2018–2030
9.3.1. Evaporative Dry Eye Syndrome
9.3.2. Aqueous Dry Eye Syndrome
9.4. Market Value Forecast, by Country, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Disease
9.5.3. By Country
10. Europe Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2018–2030
10.2.1. Diagnostic Test
10.2.1.1. Schirmer’s Test
10.2.1.2. Corneal Staining
10.2.1.3. Tear Break-up Time (TBUT)
10.2.1.4. Optical Coherence Tomography (OCT)
10.2.1.5. Tear Film Stability Analysis
10.2.1.6. Tear Osmolarity
10.2.1.7. Others
10.2.2. Treatment
10.2.2.1. Artificial Tears
10.2.2.2. Anti-inflammatory
10.2.2.2.1. Cyclosporine
10.2.2.2.2. Corticosteroid
10.2.2.2.3. Others
10.2.2.3. Punctal Plugs
10.2.2.4. Secretagogue
10.2.2.5. Others
10.3. Market Value Forecast, by Disease, 2018–2030
10.3.1. Evaporative Dry Eye Syndrome
10.3.2. Aqueous Dry Eye Syndrome
10.4. Market Value Forecast, by Country/Sub-region, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Disease
10.5.3. By Country/Sub-region
11. Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2018–2030
11.2.1. Diagnostic Test
11.2.1.1. Schirmer’s Test
11.2.1.2. Corneal Staining
11.2.1.3. Tear Break-up Time (TBUT)
11.2.1.4. Optical Coherence Tomography (OCT)
11.2.1.5. Tear Film Stability Analysis
11.2.1.6. Tear Osmolarity
11.2.1.7. Others
11.2.2. Treatment
11.2.2.1. Artificial Tears
11.2.2.2. Anti-inflammatory
11.2.2.2.1. Cyclosporine
11.2.2.2.2. Corticosteroid
11.2.2.2.3. Others
11.2.2.3. Punctal Plugs
11.2.2.4. Secretagogue
11.2.2.5. Others
11.3. Market Value Forecast, by Disease, 2018–2030
11.3.1. Evaporative Dry Eye Syndrome
11.3.2. Aqueous Dry Eye Syndrome
11.4. Market Value Forecast, by Country/Sub-region, 2018–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Disease
11.5.3. By Country/Sub-region
12. Latin America Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2018–2030
12.2.1. Diagnostic Test
12.2.1.1. Schirmer’s Test
12.2.1.2. Corneal Staining
12.2.1.3. Tear Break-up Time (TBUT)
12.2.1.4. Optical Coherence Tomography (OCT)
12.2.1.5. Tear Film Stability Analysis
12.2.1.6. Tear Osmolarity
12.2.1.7. Others
12.2.2. Treatment
12.2.2.1. Artificial Tears
12.2.2.2. Anti-inflammatory
12.2.2.2.1. Cyclosporine
12.2.2.2.2. Corticosteroid
12.2.2.2.3. Others
12.2.2.3. Punctal Plugs
12.2.2.4. Secretagogue
12.2.2.5. Others
12.3. Market Value Forecast, by Disease, 2018–2030
12.3.1. Evaporative Dry Eye Syndrome
12.3.2. Aqueous Dry Eye Syndrome
12.4. Market Value Forecast, by Country/Sub-region, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Disease
12.5.3. By Country/Sub-region
13. Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2018–2030
13.2.1. Diagnostic Test
13.2.1.1. Schirmer’s Test
13.2.1.2. Corneal Staining
13.2.1.3. Tear Break-up Time (TBUT)
13.2.1.4. Optical Coherence Tomography (OCT)
13.2.1.5. Tear Film Stability Analysis
13.2.1.6. Tear Osmolarity
13.2.1.7. Others
13.2.2. Treatment
13.2.2.1. Artificial Tears
13.2.2.2. Anti-inflammatory
13.2.2.2.1. Cyclosporine
13.2.2.2.2. Corticosteroid
13.2.2.2.3. Others
13.2.2.3. Punctal Plugs
13.2.2.4. Secretagogue
13.2.2.5. Others
13.3. Market Value Forecast, by Disease, 2018–2030
13.3.1. Evaporative Dry Eye Syndrome
13.3.2. Aqueous Dry Eye Syndrome
13.4. Market Value Forecast, by Country/Sub-region, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Disease
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share/Position Analysis, by Company, 2019
14.3. Competitive Business Strategies
14.4. Company Profiles
14.4.1. Novartis AG
14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.1.2. Company Financials
14.4.1.3. Growth Strategies
14.4.1.4. SWOT Analysis
14.4.2. Allergan plc
14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.2.2. Company Financials
14.4.2.3. Growth Strategies
14.4.2.4. SWOT Analysis
14.4.3. OASIS Medical
14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.3.2. Company Financials
14.4.3.3. Growth Strategies
14.4.3.4. SWOT Analysis
14.4.4. Santen Pharmaceutical Co., Ltd.
14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.4.2. Company Financials
14.4.4.3. Growth Strategies
14.4.4.4. SWOT Analysis
14.4.5. Johnson & Johnson
14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.5.2. Company Financials
14.4.5.3. Growth Strategies
14.4.5.4. SWOT Analysis
14.4.6. Otsuka Pharmaceutical Co., Ltd.
14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.6.2. Company Financials
14.4.6.3. Growth Strategies
14.4.6.4. SWOT Analysis
14.4.7. Advanced Tear Diagnostics
14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.7.2. Company Financials
14.4.7.3. Growth Strategies
14.4.7.4. SWOT Analysis
14.4.8. Tomey Corporation
14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.8.2. Company Financials
14.4.8.3. Growth Strategies
14.4.8.4. SWOT Analysis
14.4.9. Carl Zeiss Meditec AG
14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.9.2. Company Financials
14.4.9.3. Growth Strategies
14.4.9.4. SWOT Analysis
14.4.10. TearLab Corporation
14.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.10.2. Company Financials
14.4.10.3. Growth Strategies
14.4.10.4. SWOT Analysis
14.4.11. Bausch Health Companies, Inc.
14.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.11.2. Company Financials
14.4.11.3. Growth Strategies
14.4.11.4. SWOT Analysis
14.4.12. RegeneRx (ReGenTree, LLC)
14.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.12.2. Company Financials
14.4.12.3. Growth Strategies
14.4.12.4. SWOT Analysis
List of Tables
Table 01: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 02: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 03: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Treatment, 2018–2030
Table 04: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 05: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Disease, 2018–2030
Table 06: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 09: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 10: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Treatment, 2018–2030
Table 11: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 12: North America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Disease, 2018–2030
Table 13: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 15: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 16: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Treatment, 2018–2030
Table 17: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 18: Europe Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Disease, 2018–2030
Table 19: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Type, 2018–2030
Table 21: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 22: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Treatment, 2018–2030
Table 23: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 24: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Disease, 2018–2030
Table 25: Latin America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Type, 2018–2030
Table 27: Latin America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 28: Latin America Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Treatment, 2018–2030
Table 29: Latin America Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 30: Latin America Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, by Disease, 2018–2030
Table 31: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Type, 2018–2030
Table 33: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Diagnostic Test, 2018–2030
Table 34: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Treatment, 2018–2030
Table 35: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Anti-inflammatory, 2018–2030
Table 36: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Size (US$ Mn) Forecast, by Disease, 2018–2030
List of Figures
Figure 01: Global Dry Eye Disease Diagnostics & Treatment Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Dry Eye Disease Diagnostics & Treatment Market Value Share, by Type, 2019
Figure 03: Global Dry Eye Disease Diagnostics & Treatment Market Value Share, by Disease, 2019
Figure 04: Global Dry Eye Disease Diagnostics & Treatment Market Value Share, by Region, 2019
Figure 05: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Type, 2019 and 2030
Figure 06: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Diagnostic Test, 2019 and 2030
Figure 07: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Treatment, 2019 and 2030
Figure 08: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Anti-inflammatory, 2019 and 2030
Figure 09: Global Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn), by Diagnostic Test, 2018–2030
Figure 10: Global Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn), by Treatment, 2018–2030
Figure 11: Global Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 12: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Disease, 2019 and 2030
Figure 13: Global Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn), by Evaporative Dry Eye Syndrome, 2018–2030
Figure 14: Global Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn), by Aqueous Dry Eye Syndrome, 2018–2030
Figure 15: Global Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 16: Global Dry Eye Disease Diagnostics & Treatment Market Value Share Analysis, by Region, 2019 and 2030
Figure 17: Global Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Region, 2020–2030
Figure 18: North America Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 19: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Country, 2019 and 2030
Figure 20: North America Dry Eye Disease Diagnostics & Treatment Market Attractiveness, by Country, 2020–2030
Figure 21: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Type, 2019 and 2030
Figure 22: North America Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 23: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Diagnostic Test, 2019 and 2030
Figure 24: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Treatment, 2019 and 2030
Figure 25: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Anti-inflammatory, 2019 and 2030
Figure 26: North America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Disease, 2019 and 2030
Figure 27: North America Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 28: Europe Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 29: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2019 and 2030
Figure 30: Europe Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 31: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Type, 2019 and 2030
Figure 32: Europe Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 33: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Diagnostic Test, 2019 and 2030
Figure 34: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Treatment, 2019 and 2030
Figure 35: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Anti-inflammatory, 2019 and 2030
Figure 36: Europe Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Disease, 2019 and 2030
Figure 37: Europe Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 38: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 39: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2019 and 2030
Figure 40: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 41: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Type, 2019 and 2030
Figure 42: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 43: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Diagnostic Test, 2019 and 2030
Figure 44: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Treatment, 2019 and 2030
Figure 45: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Anti-inflammatory, 2019 and 2030
Figure 46: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Disease, 2019 and 2030
Figure 47: Asia Pacific Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 48: Latin America Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 49: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2019 and 2030
Figure 50: Latin America Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 51: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Type, 2019 and 2030
Figure 52: Latin America Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 53: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Diagnostic Test, 2019 and 2030
Figure 54: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Treatment, 2019 and 2030
Figure 55: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Anti-inflammatory, 2019 and 2030
Figure 56: Latin America Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Disease, 2019 and 2030
Figure 57: Latin America Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 58: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 59: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Country/Sub-region, 2019 and 2030
Figure 60: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 61: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Type, 2019 and 2030
Figure 62: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Type, 2020–2030
Figure 63: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Diagnostic Test, 2019 and 2030
Figure 64: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Treatment, 2019 and 2030
Figure 65: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Anti-inflammatory, 2019 and 2030
Figure 66: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Value Share (%) Analysis, by Disease, 2019 and 2030
Figure 67: Middle East & Africa Dry Eye Disease Diagnostics & Treatment Market Attractiveness Analysis, by Disease, 2020–2030
Figure 68: Market Position/Ranking Analysis, 2019, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Dry Eye Disease Diagnostics & Treatment Market
